To determine whether a limited number of FLT3+ CML cells is sufficient to repopulate after TKI treatment, we diluted FLT3+ and FLT3− cells in different ratios and then subjected them to imatinib treatment. The gene discussed is FLT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.